Patents by Inventor Shushan LIN

Shushan LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL-TARGET FUSION PROTEINS COMPRISING FGF21 AND GLP-1, CONNECTED THROUGH A FC PORTION OF AN IMMUNOGLOBULIN
    Publication number: 20250084144
    Abstract: Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight.
    Type: Application
    Filed: August 15, 2024
    Publication date: March 13, 2025
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao CHEN, Shushan LIN, Yu LI, Xiaofeng CHEN, Liang LIU, Zheng FU
  • Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin
    Patent number: 12145974
    Abstract: Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: November 19, 2024
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao Chen, Shushan Lin, Yu Li, Xiaofeng Chen, Liang Liu, Zheng Fu
  • A NOVEL ACYLATED INSULIN ANALOG
    Publication number: 20240374692
    Abstract: A novel acylated insulin analog is provided as well as a side chain compound that can be used to prepare the acylated insulin analog, a pharmaceutical composition thereof, a pharmaceutical use, an administration method and a preparation method. The acylated insulin analog can be used for the treatment of diabetes. It has the effect as a weekly preparation or a longer-acting insulin preparation and can be used for the treatment once a week or less frequently, increasing the compliance of diabetic patients.
    Type: Application
    Filed: May 23, 2022
    Publication date: November 14, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Baoye ZHENG, Dan LEI, Haigang WANG, Shushan LIN, Zhizhu ZHAN, Qian WANG, Qiuyan LIU, Yangling HU, Zilan YANG, Yan JIANG, Wenjia LI
  • USES OF FGF21 POLYPEPTIDES AND FUSION POLYPEPTIDES THEREOF
    Publication number: 20240165202
    Abstract: A method of treating fatty liver-related diseases in a patient includes administering to the patient a therapeutically effective amount of medicament manufactured from a FGF21 polypeptide, FGF21 fusion protein, or dual-fusion protein of FGF21 polypeptide and GLP-1 or a functional variant thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: May 23, 2024
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Shushan LIN, Yu LI, Xianglei GAO, Can XIE, Jiangyu YAN, Liang LIU, Xiaoping LI, Xiaofeng CHEN, Wenjia LI
  • HUMANIZED ANTI-TRKA ANTIBODIES AND USES THEREOF
    Publication number: 20230357411
    Abstract: A humanized antibody or antigen-binding fragment thereof capable of specifically recognizing TrkA and uses thereof. The antibody includes a heavy chain variable region with an amino acid sequence shown in any one of SEQ ID NO: 2-8, and a light chain variable region with an amino acid sequence shown in any one of SEQ ID NO: 10-13. The above-mentioned antibody according to the embodiments of the present invention can specifically target and bind to the TrkA receptor and block the binding of NGF and TrkA.
    Type: Application
    Filed: November 18, 2021
    Publication date: November 9, 2023
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zhiheng REN, Junji DONG, Zhuandi HE, Kezhu WANG, Jielian LU, Shushan LIN, Liang LIU, Xiang LI, Kuo ZHANG, Yan JIANG, Xiaoping LI, Xiaofeng CHEN, Wenjia LI
  • FGF21 variant, fusion protein and application thereof
    Patent number: 11679143
    Abstract: A fibroblast growth factor 21 (FGF21) variant, further to a FGF21 variant fusion protein, a protein multimer, and use thereof can significantly improve the binding ability with the target and can be used to treat metabolic diseases.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: June 20, 2023
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao Chen, Shushan Lin, Yu Li, Xiaofeng Chen, Wenjia Li, Liang Liu, Zheng Fu
  • ANTI-TRKA ANTIBODIES AND USES THEREOF
    Publication number: 20220204630
    Abstract: An antibody or an antigen-binding fragment thereof is capable of specifically recognizing TrkA and uses thereof. The antibody contains a CDR sequence selected from at least one of the following or an amino acid sequence having at least 95% identity with it: heavy chain variable region CDR sequences: SEQ ID NO: 1˜27, light chain variable region CDR sequences: SEQ IN NO: 28˜54. The above antibody can specifically targeted-bind to the TrkA receptor and block the binding of NGF to TrkA.
    Type: Application
    Filed: May 28, 2020
    Publication date: June 30, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao CHEN, Zhiheng REN, Zhuandi HE, Jielian LU, Shushan LIN, Tingting YU, Xiling WEI, Xufang WANG, Le XU, Junji DONG, Xiang LI, Kuo ZHANG, Xueyao YANG, Linfeng GUO, Xiaoping LI, Xiaofeng CHEN, Wenjia LI
  • DUAL-TARGET FUSION PROTEINS COMPRISING THE FC PORTION OF AN IMMUNOGLOBULIN
    Publication number: 20220127322
    Abstract: Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight.
    Type: Application
    Filed: March 14, 2018
    Publication date: April 28, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao CHEN, Shushan LIN, Yu LI, Xiaofeng CHEN, Liang LIU, Zheng FU
  • A POLYPEPTIDE MOLECULE AND APPLICATION THEREOF
    Publication number: 20220064244
    Abstract: An FGF21 polypeptide has one or more of the following properties: stable structure, long half-life, low immunogenicity, high biological activity, and enhanced glucose-lowering and lipid-lowering activities. A fusion protein or immunoconjugate includes the FGF21 polypeptide.
    Type: Application
    Filed: March 4, 2020
    Publication date: March 3, 2022
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao CHEN, Shushan LIN, Yu LI, Xiaoping LI, Xiaofeng CHEN, Wenjia LI, Liang LIU, Zheng FU
  • FGF21 VARIANT, FUSION PROTEIN AND APPLICATION THEREOF
    Publication number: 20210196794
    Abstract: A fibroblast growth factor 21 (FGF21) variant, further to a FGF21 variant fusion protein, a protein multimer, and use thereof can significantly improve the binding ability with the target and can be used to treat metabolic diseases.
    Type: Application
    Filed: January 29, 2019
    Publication date: July 1, 2021
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chao CHEN, Shushan LIN, Yu LI, Xiaofeng CHEN, Wenjia LI, Liang LIU, Zheng FU